8 research outputs found

    Sustainability considerations in membrane-based technologies for industrial effluents treatment

    Get PDF
    Treatment of industrial effluents (EFs) from the polluted wastewater sources using membrane technologies is an effective and attractive alternative to overcome the weaknesses of some of the conventional wastewater treatment processes, especially when dealing with EFs loaded with recalcitrant organic pollutants and toxic substances. The application of various polymeric and inorganic membrane based technologies to be used for the treatment of industrial EFs has attracted a considerable attention in the past decades. In this regard, a critical discussion on the sustainability of various aspects of membrane technologies would promote the commercialization of these technologies. In this review, various sustainability criteria in technical, economic, environmental, and social categories have been considered for a critical discussion on the current status and improvement opportunities of membrane technologies for the treatment of industrial EFs. While the application of polymeric membranes has been restricted by some bottlenecks to deal with some industrial effluents, metal oxides fabricated ceramic membranes, and especially those fabricated with nanostructured materials such as nano-zeolites, those made of metal organic frameworks as well as carbon-based fabricated membranes have shown a promising performance in the rejection of recalcitrant organic pollutants. In addition, the combinations of inorganic membrane technologies with other novel methods such as advanced oxidation processes (e.g., using engineered nanomaterials) can be considered among the best options to deal with such highly polluted effluents.publishe

    Methods for Preparing Carbon Sorbents from Lignin (Review)

    No full text

    Six-year multicenter study on short-term peripheral venous catheters-related bloodstream infection rates in 204 intensive care units of 57 hospitals in 19 cities of India: International Nosocomial Infection Control Consortium (INICC) findings

    No full text

    Attraction of Likenesses: Mechanisms of Self-Association and Compartmentalization of Eukaryotic Chromatin

    No full text

    International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

    No full text
    •We report INICC device-associated module data of 50 countries from 2010-2015.•We collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.•DA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.•Device utilization ratio in the INICC ICUs was similar to CDC-NHSN's. Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific. Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days. Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs. Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically
    corecore